Genprex (GNPX) Posts Earnings Results, Misses Expectations By $0.09 EPS

Genprex (NASDAQ:GNPX) announced its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09), Fidelity Earnings reports.

Shares of GNPX stock opened at $1.68 on Tuesday. Genprex has a 52 week low of $0.95 and a 52 week high of $19.45.

GNPX has been the subject of a number of recent analyst reports. Maxim Group downgraded shares of Genprex from a “buy” rating to a “hold” rating in a report on Monday. ValuEngine downgraded shares of Genprex from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.

ILLEGAL ACTIVITY WARNING: “Genprex (GNPX) Posts Earnings Results, Misses Expectations By $0.09 EPS” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://sportsperspectives.com/2019/04/02/genprex-gnpx-posts-earnings-results-misses-expectations-by-0-09-eps.html.

About Genprex

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.